SCIASCIA THOMAS 4

What Happened

• Thomas Sciascia, Chief Scientific Officer of Trevi Therapeutics (TRVI), received a grant/award of derivative securities covering 85,000 shares on February 19, 2026. The Form 4 records the acquisition amount as $0.00 because this is an equity award (option/other derivative), not a cash purchase or sale.

Key Details

• Transaction date: 2026-02-19 (reported on Form 4 filed 2026-02-20) — appears timely.
• Transaction type/code: A (Award/Grant of a derivative security).
• Amount: 85,000 shares underlying the granted option; price reported as $0.00 (grant).
• Vesting: Per footnote, the 85,000 underlying shares vest in equal monthly installments through February 19, 2030, subject to continued service.
• Shares owned after transaction: Not specified in this Form 4.
• Filing timeliness: Reported the next day (not marked late).

Context

• This was an equity award (options/derivative grant), a common form of executive compensation tied to continued service via the multi-year vesting schedule. Such grants do not immediately increase free-tradable share count until options vest and are exercised; they are different from open-market purchases or sales that signal immediate insider buying or selling.